中国经济网北京11月17日讯 科兴制药(688136.SH)11月14日发布股东询价转让计划书。本次拟参与 科兴制药首发前股东询价转让（以下简称"本次询价转让"）的股东为科益医药；出让方拟转让股份的总 数为10,062,800股，占公司总股本的比例为5.00%；本次询价转让为非公开转让，不通过集中竞价交易 方式或大宗交易方式进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后6个 月内不得转让；本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资者。 | 拟转让股东 拟转让股份 | | 占总股本 | 占所持股份比例 | 转让原因 | | --- | --- | --- | --- | --- | | 名称 | 数量(股) | 比例 | (截至2025年11月14日) | | | 科益医药 | 10,062,800 | 5.00% | 9.17% | 自身经营发展需要 | 本次询价转让出让方科益医药为公司控股股东，持有公司股份比例超过5%。公司董事长邓学勤通 过科益医药间接持有公司股份。 按照科兴制药11月14日收盘价37.55元计算，科益医药本次询价转让股份对应总市值约3.78亿元。 ...

Policy Developments - The National Health Commission's Director Lei Haichao emphasized the importance of planning for the "14th Five-Year Plan" to accelerate the construction of a healthy China and promote high-quality population development [2] - Key tasks include optimizing the function and layout of medical institutions, implementing strong foundational healthcare projects, and enhancing public health capabilities [2] Pharmaceutical Industry Updates - Bai Cheng Pharmaceutical's subsidiary received clinical trial approval for BIOS2242, a drug for treating acute ischemic stroke, with no current approvals for this product domestically or internationally [5] - Fosun Pharma's subsidiary received FDA approval for HLX11, a biosimilar drug for HER2-positive breast cancer, with applications for registration in China and Europe also accepted [6] Market Movements - Kexing Pharmaceutical's controlling shareholder plans to transfer 5% of its shares through an inquiry-based transfer due to operational needs [8][9] - Enwei Pharmaceutical announced a 20 million yuan investment to establish a fund focused on healthcare and technology sectors, with a total fund size of 201 million yuan [10] Major Industry Events - Guangxi's pharmaceutical exports reached a record high, with a year-on-year increase of 27.23% in the first three quarters of the year [13] - Samsung Medical's subsidiary is a candidate for a procurement project with an estimated value of 168 million yuan, which could positively impact the company's performance [14] Corporate Governance Changes - Haocen Medical announced a change in control, with no single controlling party, following the termination of a cooperation agreement [16] - Yifeng Pharmacy's executives plan to reduce their holdings by a total of 0.0176% of shares due to personal financial needs [17]

Policy Developments - The National Health Commission's Secretary Lei Haichao conducted research in Guangxi, focusing on pediatric and mental health, grassroots medical services, and public hospital reforms, emphasizing the need for a robust health system and high-quality population development [2] - The "14th Five-Year" plan highlights strengthening grassroots healthcare, promoting the distribution of quality medical resources, and enhancing public health capabilities [2] Drug and Medical Device Approvals - Baicheng Pharmaceutical's subsidiary received clinical trial approval for BIOS2242, a treatment for acute ischemic stroke, with no prior approvals for this product globally [5] - Fosun Pharma's subsidiary received FDA approval for HLX11, a biosimilar for HER2-positive breast cancer, with applications pending in China and Europe [6] Capital Market Activities - Kexing Pharmaceutical's controlling shareholder plans to transfer 5% of its shares, citing operational needs, with the transfer process managed by China International Capital Corporation [8] - Enwei Pharmaceutical announced a 20 million yuan investment in a venture capital fund focusing on healthcare and technology, with potential uncertainties regarding returns [10] - Pfizer completed the acquisition of Metsera for $10 billion, a company focused on developing drugs for obesity and cardiovascular diseases [11] Industry Developments - Guangxi's pharmaceutical exports reached a record high, growing 27.23% year-on-year in the first three quarters [13] - Samsung Medical's subsidiary is a candidate for a 168 million yuan procurement project with the State Grid, which could positively impact the company's performance [14] Shareholder Movements - Haocen Medical announced a change in control, with no single controlling party, following a partnership agreement termination [16] - Yifeng Pharmacy executives plan to reduce their holdings by a combined 0.0176% of shares due to personal financial needs [17][18]

Core Viewpoint - Recently, Sinovac Biotech (688136.SH) has received approval from Bolivia's National Medicines and Health Technologies Authority (AGEMED) for its biosimilar product, Bevacizumab, marking the fifth country where this product has been approved following its collaboration with Easton Pharmaceutical [1] Group 1: Product Approval and Market Expansion - Bevacizumab is a commonly used drug in oncology, applicable for various cancers including metastatic colorectal cancer, advanced/metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian cancer, tubal cancer, primary peritoneal cancer, and cervical cancer [1] - The approval in Bolivia is part of a broader trend, as Sinovac's pharmaceutical exports to emerging markets such as ASEAN, Latin America, and Africa are steadily increasing, with Latin America seeing an 11.4% growth [1] - Sinovac has established a subsidiary in Latin America and formed a localized operational team to enhance market penetration and improve drug accessibility in the region [1] Group 2: International Registration Progress - Since the beginning of this year, multiple Sinovac products have received market approval in various countries, with Bevacizumab biosimilar already registered in five countries including Pakistan and Indonesia [1] - There are over twenty additional countries where registration efforts for the product are rapidly advancing [1]

证券代码：688136 证券简称：科兴制药 公告编号：2025-094 科兴生物制药股份有限公司 股东询价转让计划书 股东深圳科益医药控股有限公司（以下简称"科益医药"或"出让方"）保 证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性 和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 1 重要内容提示： 本次拟参与科兴制药首发前股东询价转让（以下简称"本次询价转让"） 的股东为科益医药； 出让方拟转让股份的总数为 10,062,800 股，占公司总股本的比例为 5.00%； 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式 进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实施 本次询价转让。截至 2025 年 11 月 ...

科兴制药(688136.SH)披露股东询价转让计划书，本次拟参与本次询价转让的股东为科益医药，拟转让 股份的总数为1006.28万股，占公司总股本的比例为5%。 ...

Group 1: Company Announcements - 合富中国's stock price increased by 256.29% over 14 trading days, significantly outperforming the industry and Shanghai Composite Index, leading to a suspension for verification starting November 17 [1] - 工业富联's GB300 achieved mass production in Q3, with improved yield and testing efficiency, positively impacting Q4 gross margin [2] - 天孚通信's controlling shareholder plans to transfer 8.5 million shares, representing 1.09% of total equity, due to personal funding needs [4] - 璞泰来 plans to invest 7.6 billion yuan in a new integrated film coating project, aiming to meet growing demand in the battery and energy storage sectors [5] - 电投能源 intends to acquire 100% of Baiyin Hua Coal Power for 11.149 billion yuan, financing through share issuance and cash [6] - 中微公司 reported that a shareholder completed a reduction of 12.52 million shares, totaling 3.351 billion yuan [7] - 瑞德智能 plans to invest 10 million yuan in a leading company in the power plant robotics sector [8] - 盘古智能 aims to acquire control of a petrochemical company by purchasing 11.97% of its shares for 24.64 million yuan [9] - 泰达股份 signed a memorandum for a waste-to-energy project in Egypt [10] - 杭氧股份 is set to establish a venture capital fund focusing on low-temperature technology and nuclear fusion [11] Group 2: Financial Performance and Regulatory Approvals - 复星医药's subsidiary received FDA approval for a biosimilar drug, with applications pending in China and Europe [21] - 长春高新 received approval for a clinical trial of a new growth hormone drug, with no similar products currently available in China [20] - 海辰药业 obtained a drug registration certificate for a new injection product [22] - 上海机场 reported a 12.46% year-on-year increase in passenger throughput for October [23] Group 3: Shareholder Actions - 深桑达 A plans to publicly transfer 80% of a subsidiary's shares with a minimum price of 1.857 billion yuan [12] - 中电港's major shareholder reduced its stake by 1% between October 31 and November 13 [15] - 康龙化成's major shareholders plan to collectively reduce their holdings by up to 1.5% [16] - 科兴制药's controlling shareholder intends to transfer 5% of its shares [17]

智通财经APP讯，科兴制药(688136.SH)披露股东询价转让计划书，本次拟参与本次询价转让的股东为 科益医药，拟转让股份的总数为1006.28万股，占公司总股本的比例为5%。 ...

中国国际金融股份有限公司 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创板上 市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上海证券 交易所科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下简称"《询 价转让和配售指引》"）等相关规定，中金公司对参与本次询价出让方的相关资格进 行了核查。 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见如下： 一、本次询价转让的委托 中金公司已收到出让方关于本次询价转让的委托，委托中金公司组织实施本次询 价转让。 二、关于参与本次询价转让股东相关资格的核查情况 （一）核查过程 关于科兴生物制药股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国国际金融股份有限公司（以下简称"中金公司"）受科兴生物制药股份有限 公司（以下简称"科兴制药"）股东深圳科益医药控股有限公司（以下简称"科益医 药""出让方"）委托，组织实施本次科兴制药股东向特定机构投资者询价转让（以 下简称"本次询价转让"）。 4、出让方不存在《上市公司股东减持股份管理暂行办法》《上海证券交易所上市 公司自律监管指引第 15 号——股东 ...

格隆汇11月14日丨科兴制药(688136.SH)公布，本次拟参与科兴制药首发前股东询价转让（简称"本次询 价转让"）的股东为科益医药；出让方拟转让股份的总数为10,062,800股，占公司总股本的比例为 5.00%。 ...